Mutated Non-Toxic E. coli Enterotoxins as Anti-Inflammatory Agents
Background
Tulane University is actively seeking commercial entities to further develop and commercialize novel anti-inflammatory compounds derived from mutated non-toxic E. coli enterotoxins.
Applications
Treatment of several inflammatory diseases including but not limited to Irritable Bowel Disease (IBD)/ Colitis, Athsma, Dermatitis/Psoriasis, Rheumatoid and Psoriatic Arthritis, and Nephritis
Able to target a large family of inflammatory diseases depending on route of administration. Lower side-effects than current treatments of IBD which have chronic and short term side effects that can worsen the disease state. Can be administered orally, buccally, topically.
Able to target a large family of inflammatory diseases depending on route of administration. Lower side-effects than current treatments of IBD which have chronic and short term side effects that can worsen the disease state. Can be administered orally, buccally, topically.
Current Work
This technology has been tested extensively in animal models of IBD and colitis. The discovered mechanism of action has indications in other inflammatory disease states.
Inventors
Intellectual Property
Available For
Exclusive License in a Field
Non-exclusive License
Scientific Collaboration
